Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Peritoneal Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma 3 Stomach Neoplasms 2 Neoplasms 2 Neoplasms, Glandular and Epithelial 1 EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1 Ascites 1 Adenocarcinoma 1

Interventions

Gemcitabine 27 Fluorouracil 25 Oxaliplatin 21 Cisplatin 19 Leucovorin 17 Bevacizumab 15 130-nm albumin-bound paclitaxel 13 Docetaxel 12 Capecitabine 12 Albumin-Bound Paclitaxel 12 Paclitaxel 11 Irinotecan 10 Carboplatin 9 pembrolizumab 7 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Erlotinib Hydrochloride 6 Cyclophosphamide 6 Trastuzumab 5 Ramucirumab 5 Ipilimumab 4 Everolimus 4 Crizotinib 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × catumaxomab × Clear all

NCT01504256 2018-01-23

CatuNeo

AIO-Studien-gGmbH

Phase 2 Completed

Adenocarcinoma, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡